News

VaLogic Bio Acquires Facility Logix to Expand Life Sciences Facility Services

VaLogic Bio, a platform company of 424 Capital and a leading provider of compliance and SaaS services to the life sciences industry, proudly announces the acquisition of Facility Logix (FLGX), a renowned firm specializing in planning, developing, and project management for life sciences facilities. This acquisition aligns with VaLogic Bio’s strategic vision to enhance its capabilities and broaden its footprint in the life sciences sector.

With this acquisition, VaLogic Bio will leverage Facility Logix’s current service offerings to build a market-leading, full-service outsourced solutions platform. This platform aims to enable life science and biotechnology companies to remain GMP compliant through advisory, project management, procurement, technical equipment servicing, facility design/engineering and construction, environmental monitoring, and CQV services. These services will help clients run their labs and manufacturing suites more efficiently, allowing them to focus on advancing life-saving therapeutics. The combined company provides clients an unparalleled suite of services, from initial facility concept to operational readiness and ongoing compliance.

As part of the acquisition, Pat Larrabee, formerly the CEO and founder of Facility Logix, will become the Vice President of Advisory Services and join the VaLogic Bio leadership team.

The former Facility Logix team will continue to operate out of its Montgomery County, Maryland office in Burtonsville. With its proven track record, the team will continue to deliver high-quality, conflict-free services, ensuring a seamless and uninterrupted transition for existing clients and partners.

“The successful relationship between our firms has developed over many years of working together to support mutual clients in the Maryland market,” noted VaLogic Bio CEO Bill Robertson. “We are enthusiastic about permanently joining forces and further expanding our services and client base. Pat is well respected as a trusted advisor and leader and has deep national market knowledge.”

“We are excited about joining forces with VaLogic Bio,” commented Larrabee.

With the acquisition of Facility Logix, VaLogic Bio’s team now totals 72 employees, with offices in Texas and two offices in Maryland. This acquisition represents a significant step forward in VaLogic Bio’s unwavering commitment to simplifying compliance and ensuring peace of mind for life sciences organizations. By combining the strengths of both companies, VaLogic Bio is well-positioned to lead the industry in delivering innovative, efficient, and compliant solutions for life sciences facilities.

“I am very proud of our team’s capabilities and our portfolio of work over the past two decades,” said Larrabee. “And with the added capabilities of VaLogic Bio and the financial support of 424 Capital, we are poised to capture additional market share.”

For more information about the acquisition or to learn more about the services offered by VaLogic Bio, please visit www.valogicbio.com

Recent News

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and

06/02/2026

Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development

Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, today announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. In conjunction with the closing of the Series B financing,

06/02/2026

GEN Names BioHealth Capital Region a Top 3 U.S. Biopharma Cluster for Fourth Year in a Row

The BioHealth Capital Region, spanning Maryland, Virginia, and Washington, D.C., has once again been named one of the nation’s Top 3 biopharma clusters by Genetic Engineering & Biotechnology News (GEN), marking the region’s fourth consecutive year in the Top 3. GEN’s 2026 “Top 10 U.S. Biopharma Clusters” ranking was authored by Alex Philippidis, Senior Business